Abstract
GnRH antagonists have several clinical applications in prostate cancer, regulation of ovulation induction in females, breast cancer, male contraception and others. Antagonists differ from natural GnRH decapeptide in having five or more amino acid substitutions, whereas most of the antagonists are available as subcutaneous (SC) formula for injection some are formulated as a depot formulation for sustained release (e.g., Cetrorelix, Degarelix). Systemic delivery of cetrorelix acetate by intratracheal route can be achieved using dry powder for inhalation of the adhesive mixture when the powder deposition reaches stage four. The oral route for systemic delivery of peptide without its degradation can be achieved using gastrointestinal permeation enhancement technology GIPET® provided by acyline.
Keywords: Cetrorelix, extrusion, GnHR antagonist, microparticles, peptide, subcutaneous, testesteron.
Current Drug Delivery
Title:Delivery of Peptidic Gonadotropin Releasing Hormone Antagonists
Volume: 15 Issue: 5
Author(s): Rawda Y. AlSheyyab*, Bashar M. Al-Taani, Rana M. Obeidat, Motasem M. Alsmadi, Rafeef K. Masaedeh and Raghda N. Sabat
Affiliation:
- Jordan University of Science and Technology, Pharmaceutical Technology, Irbid, Jordan,Jordan
Keywords: Cetrorelix, extrusion, GnHR antagonist, microparticles, peptide, subcutaneous, testesteron.
Abstract: GnRH antagonists have several clinical applications in prostate cancer, regulation of ovulation induction in females, breast cancer, male contraception and others. Antagonists differ from natural GnRH decapeptide in having five or more amino acid substitutions, whereas most of the antagonists are available as subcutaneous (SC) formula for injection some are formulated as a depot formulation for sustained release (e.g., Cetrorelix, Degarelix). Systemic delivery of cetrorelix acetate by intratracheal route can be achieved using dry powder for inhalation of the adhesive mixture when the powder deposition reaches stage four. The oral route for systemic delivery of peptide without its degradation can be achieved using gastrointestinal permeation enhancement technology GIPET® provided by acyline.
Export Options
About this article
Cite this article as:
AlSheyyab Y. Rawda *, Al-Taani M. Bashar , Obeidat M. Rana , Alsmadi M. Motasem , Masaedeh K. Rafeef and Sabat N. Raghda , Delivery of Peptidic Gonadotropin Releasing Hormone Antagonists, Current Drug Delivery 2018; 15 (5) . https://dx.doi.org/10.2174/1567201815666180214142300
DOI https://dx.doi.org/10.2174/1567201815666180214142300 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gene Sets of Gene Ontology are More Stable Diagnostic Biomarkers than Genes in Oral Squamous Cell Carcinoma
Current Bioinformatics Decreased Serum/Plasma Vitamin D levels in SLE Patients: A Meta-Analysis
Current Pharmaceutical Design Supplementation, Optimal Status, and Analytical Determination of Vitamin D: Where are we Standing in 2012?
Anti-Cancer Agents in Medicinal Chemistry Designing Promiscuous Drugs? Look at What Nature Made!
Letters in Drug Design & Discovery Bioaccessibility of Functional Ingredients
Current Nutrition & Food Science Subject Index To Volume 6
Current Molecular Medicine Different Aspects of Head and Neck Squamous Cell Carcinoma: Cancer Stem Cells, their Niche and Targeted Therapy
Current Stem Cell Research & Therapy ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry DNA Binding Mode of Transition Metal Complexes, A Relationship to Tumor Cell Toxicity
Current Medicinal Chemistry Genetic Manipulation to Increase Lipase Production in Microorganisms – A Recent Review
Current Biochemical Engineering (Discontinued) Gastrin-Releasing Peptide Receptor as a Molecular Target for Psychiatric and Neurological Disorders
CNS & Neurological Disorders - Drug Targets Multiple Hsp70 Isoforms in the Eukaryotic Cytosol: Mere Redundancy or Functional Specificity?
Current Genomics Medicinal Compound Celastrol As a Potential Clinical Anticancer Drug: Lessons Learned From Preclinical Studies
Clinical Cancer Drugs Discovery of Hedgehog Antagonists for Cancer Therapy
Current Medicinal Chemistry Global Gene Expression in Classification, Pathogenetic Understanding and Identification of Therapeutic Targets in Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Positron Emission Tomography and Computer Tomography (PET/CT) in Prostate, Bladder, and Testicular Cancers
Current Medicinal Chemistry The Functional Role of Long Non-coding RNA UCA1 in Human Multiple Cancers: a Review Study
Current Molecular Medicine p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design RGD-based Therapy: Principles of Selectivity
Current Pharmaceutical Design Cruciferous Plants: Phytochemical Toxicity Versus Cancer Chemoprotection
Mini-Reviews in Medicinal Chemistry